Medicare rolls out temporary obesity-drug coverage via Bridge program with $50 copay

Medicare will temporarily cover obesity GLP-1 medications under the Bridge program starting July 1, with a flat $50 monthly copay for eligible Part D beneficiaries and no deductible contribution toward costs. Drugs like Wegovy and Zepbound are included, and eligibility is based on BMI thresholds and related health conditions; the coverage runs through an 18-month demonstration ending in 2027 unless extended, with prior-authorization handled by providers and Humana. While the move could unlock millions of potential patients for Novo Nordisk and Lilly, concerns include surge in demand, administrative burden, and the uncertain long-term viability beyond the demonstration, as well as ongoing policy debates such as Balance and the Treat and Reduce Obesity Act.